Horizon Discovery, formerly of PerkinElmer, and now part of the Revvity family, drives the application of gene editing and gene modulation to enable world-leading academic institutes, pharmaceutical and biotechnology companies, as well as clinical diagnostic laboratories, to identify the genetic drivers behind human disease, develop and validate diagnostic workflows, and deliver new therapies for precision medicine. With more than a decade of experience in the engineering of cell lines, Horizon offers innovative tools and services based upon the ability to modulate, or permanently alter, the function of almost any gene in human and other mammalian cell lines. Horizon is headquartered in Cambridge, UK with offices in USA and Japan.